Pharmacokinetics of Intravenous Melatonin in Preschool‐Aged Pediatric Surgical Patients Authors: Anne Louise de Barros Garioud, Arash Afshari, Lau Romlund Halgreen, Kristian Østergaard Nielsen, Lars Peter Kloster Andersen Published: 2026 ABSTRACT ABSTRACTBackgroundMelatonin may have several beneficial clinical effects in the perioperative setting. In children, it has been studied for preoperative anxiety, postoperative pain, and emergence delirium. Melatonin's pharmacokinetic profile is well‐known in adults, but data in young children are sparse. We aimed to investigate the pharmacokinetic parameters of an intravenous intraoperative bolus of melatonin in pediatric surgical patients.MethodsWe enrolled 20 participants aged 1–6 years undergoing general anesthesia for elective surgery to receive an intravenous melatonin dose of 0.15 mg·kg−1 before end of surgery. A total of six blood samples were drawn from each participant at the following time points: baseline, 0, 15, 30, 60, and 90 min post‐injection. Plasma melatonin concentrations were determined with High‐Performance Liquid Chromatography with Fluorescence Detection (HPLC‐FLD). Pharmacokinetic parameters were estimated with non‐compartmental analysis. Clinical outcomes were recorded.ResultsWe included 98 samples in the pharmacokinetic analysis. We found a maximum plasma concentration (C max) of 416 298 [IQR 322 230–508 006] pg·mL−1 and an elimination half‐life (t 1/2) of 35.2 (SD 8.4) minutes. Clearance (CL) was 0.0183 (SD 0.0039) L·min−1·kg−1 and volume of distribution (Vd) 0.92 (SD 0.27) L·kg−1. There were no cases of emergence delirium, mean maximum pain (FLACC) score was 1.3 (SD 2.0), and time to awakening and discharge readiness averaged one and two hours, respectively. Adverse events could be attributed to routine postoperative symptoms.ConclusionAdministering intravenous melatonin in a dose of 0.15 mg·kg−1 in 1–6‐year‐olds yielded pharmacokinetic characteristics comparable to those reported in adults. The observed postoperative events were consistent with expected perioperative findings. These data support dose selection for trials investigating the perioperative use of melatonin in children.Trial RegistrationCTIS: EU CT 2024‐517592‐20. Clinicaltrials.gov: NCT05541276 (registered 12/09‐2022)Keywords: anxiety, emergence delirium, melatonin, pharmacokinetics, postoperative pain Clinical Implications What is Already Known Melatonin has anxiolytic and analgesic properties and may reduce emergence delirium in children. The pharmacokinetics of intravenous melatonin have not previously been described in preschool aged children. Melatonin has anxiolytic and analgesic properties and may reduce emergence delirium in children. The pharmacokinetics of intravenous melatonin have not previously been described in preschool aged children. What New Information This Study Adds An intravenous bolus dose of 0.15 mg of melatonin demonstrated pharmacokinetic parameters comparable to adults, thus informing dosing strategies for future trials. An intravenous bolus dose of 0.15 mg of melatonin demonstrated pharmacokinetic parameters comparable to adults, thus informing dosing strategies for future trials. Introduction Melatonin (N‐acetyl‐5‐methoxytryptamine) is a neurohormone secreted by the pineal gland. Melatonin has documented sedative, anxiolytic, antioxidative, and analgesic properties [1, 2, 3]. In pediatric anesthesia, melatonin has primarily been investigated for its anxiolytic properties as premedication during the surgical course [4]. An increasing body of evidence also points towards a potential effect on emergence delirium, which is a common complication in pediatric patients undergoing general anesthesia and surgery [5]. Melatonin is considered safe for clinical use in children [6], although the effects of long‐term use are still being investigated [7]. Studies investigating melatonin as premedication have administered oral formulations [5]. However, the bioavailability of melatonin administered orally is low (approximately 15%) with substantial inter‐individual variability [8]. In the MELA‐PAED trial [9], we investigate whether an intraoperative intravenous bolus of melatonin can reduce the incidence of emergence delirium in preschool‐aged pediatric patients undergoing general anesthesia and surgery. The pharmacokinetic profile of melatonin is well‐documented in adults [8]. In pediatric patients, however, pharmacokinetic data are sparse [10, 11, 12]. As a part of the MELA‐PAED trial, we have performed an open‐label pharmacokinetic sub‐study. The aim of this study was to investigate the pharmacokinetic profile of intravenous melatonin in preschool‐aged pediatric surgical patients. Materials and Methods The study was approved as a sub‐study of the MELA‐PAED trial [9] by the Danish Health Research Ethics Committee System and the Danish Medicines Agency and has been transitioned to the European Clinical Trials Information System (CTIS) (EU CT number: 2024‐517592‐20). The study is also registered on ClinicalTrials.gov (NCT05541276). This study has been monitored by the GCP‐unit, University Hospital of Copenhagen. Written informed consent was given by legal representatives of participants before study enrollment. Participants Between January 2025 and June 2025, we enrolled 20 participants at the Department of Anesthesiology, Juliane Marie Center, Rigshospitalet, Denmark. Inclusion criteria were 1–6 years of age and a scheduled elective surgical procedure under general anesthesia with an expected duration of at least 30 min. Exclusion criteria were daily medication with melatonin or known allergy or contraindications to the drug and/or excipients. Formulation In Denmark, melatonin is currently marketed as oral tablets or as an oral solution. There is no commercially available formulation of melatonin for intravenous use. In collaboration with the Glostrup Pharmacy (Glostrup, Denmark), we developed an aqueous solution of melatonin for injection 1 mg·mL−1 suitable for pediatric use in ampoules of 5 mL. The solution was produced in accordance with Good Manufacturing Practice (GMP) [13] as an Investigational Medicinal Product (IMP). The production was performed by Glostrup Pharmacy in a GMP‐classified facility, and the ampoules were sterilized using an autoclave. The Active Pharmaceutical Ingredient Melatonin (CAS number 73‐31‐4) was produced by Flamma Group (Chignolo d'Isola, Italy) and imported to Glostrup Pharmacy by Farmalabor SRL (Canosa di Puglia, Italy). Stability was assessed by Glostrup Pharmacy with a 12‐month temperature‐accelerated study (40°C/75% RH [relative humidity]). Assay and impurities testing, Total Aerobic Microbial Count and Total Yeast and Mold Count (TAMC/TYMC), bacterial endotoxins test, and sterility test were all performed by Eurofins Biopharma Product Testing A/S (Glostrup, Denmark). The product was Qualified Person (QP)‐released for the study by Glostrup Pharmacy. Study Procedures and Data Collection Study data were collected and managed using REDCap, hosted by the Capital Region, Denmark [14]. Consent was given in person or with the e‐consent framework [15]. Participants were prepared for general anesthesia with topical local anesthesia (lidocaine/prilocaine 25 + 25 mg·g−1) applied to the dorsum of both hands, 1 h before scheduled surgery. Premedication with midazolam was allowed. General anesthesia was induced/maintained intravenously with propofol/remifentanil or by inhalation with sevoflurane. Opioids, paracetamol, ibuprofen, and peripheral or central nerve blocks were administered at the discretion of the anesthesiologist. Participants were transferred post‐surgery to the post‐anesthetic care unit (PACU). Discharge from PACU adhered to Danish national guidelines, which include a checklist similar to the modified Aldrete score on a 4‐point system. Before surgery, information on participants' medical history—including daily medications—was obtained. Preoperative anxiety was assessed in the holding area and again immediately prior to anesthetic induction employing the modified Yale Preoperative Anxiety Score‐Short Form (mYPAS‐SF). Vital signs were continuously monitored during general anesthesia and PACU stay. In the PACU, participants' postoperative pain was assessed employing the Faces, Legs, Activity, Cry, Consolability scale (FLACC) every 15 min. Correspondingly, emergence agitation was assessed using the Watcha scale. Occurrence of postoperative nausea and vomiting (PONV) was also recorded. Participants were assessed for emergence delirium on the Pediatric Anesthesia Emergence Delirium (PAED) scale 10 min after awakening. Time‐to‐awakening and time to discharge from PACU were noted. Finally, a follow‐up telephone interview with parents was performed the day after surgery employing the Post Hospitalization Behavior Questionnaire for Ambulatory Surgery (PHBQ‐AS). On the PHBQ‐AS, a score of 3 signals no behavioral change, whereas scores above 3 indicate more new‐onset maladaptive behaviors. Adverse events were recorded according to the MedDRA terminology during the day of surgery and at the follow‐up interview. Medical records were accessed 30 days after surgery in order to record any serious adverse events, including possible rehospitalization. Drug Administration and Blood Sampling Approximately 30 min before the end of surgery, melatonin was administered as an intravenous bolus of 0.15 mg·kg−1 with a 5 mL syringe (maximum 5 mg). A total of six blood samples (2 mL each) were collected in EDTA tubes via an indwelling venous cannula at baseline (before injection), immediately after injection (0–2 min), and at 15, 30, 60, and 90 min after intravenous injection. Plasma was separated by centrifugation at 2000 g for 10 min at 4°C with a refrigerated centrifuge (Micro Star 30R, VWR International bvba, Leuven, Belgium). Plasma samples of a minimum of 0.6 mL were frozen in cryovials and stored at −20°C pending analysis. Melatonin Assay Extraction Plasma samples (100 μL) and calibrators (100 μL) were added to borosilicate sample tubes and diluted with distilled water (900 μL), followed by the addition of dichloromethane (5 mL). The borosilicate tubes were capped off with polypropylene caps and mixed on a vertical rotating mixer at 20 rpm. The tubes were then centrifuged at 690 g, and the aqueous phase was very carefully removed by aspiration. The resulting organic phase was frozen on an ethanol/dry ice bath for 2 min, and the contents of the sample tubes were poured into clean borosilicate sample tubes. The dichloromethane was evaporated under a very gentle stream of nitrogen at 30°C, and the resulting remnant was reconstituted in the mobile phase (60 μL) of the HPLC method, which was transferred to a Verex μVial i3 Qsert HPLC vial. Chromatography Chromatography was performed on a Dionex UltiMate 3000 HPLC consisting of an HPG‐3200SD pump, a WPS‐3000TSL autosampler, a TCC‐3000SD column oven, and a FLD‐3100 fluorescence detector. A hypersil gold column (100 × 2.1 mm, 1.9 μm particle size) was used, and the HPLC mobile phase consisted of 70 mM NaH2PO4 adjusted to pH 3 with H3PO4 as the aqueous phase and methanol as the organic phase in a 75:25 ratio at a flow rate of 0.2 mL·min−1 at 30°C. The fluorescence detector was set at an excitation wavelength of 290 nm and an emission wavelength of 345 nm with a sensitivity of 5. Injection volume was 10 μL. Calibration was done by external calibration via pooled plasma spiked with melatonin at 400, 4000, 40 000, and 400 000 pg·mL−1, using peak height as the detector response. The linear correlation for the calibration curve was y = 0.00524x (r 2 = 0.99906). Intra‐assay precision by coefficient of variation (CV%) was found to be 4.13% for 10 spiked plasma samples at 300 000 pg·mL−1 and 5.36% for 10 spiked plasma samples at 300 pg·mL−1. Inter‐assay precision by CV% was found to be 4.97% for 3 spiked plasma samples at 300 000 pg·mL−1, and 4.66% for 4 spiked plasma samples at 300 pg·mL−1. The lower limit of quantification (LLOQ) was 300 pg·mL−1, and the upper limit of quantification was 560 000 pg·mL−1. Samples containing higher amounts of melatonin than the upper limit of quantification were diluted accordingly. Pharmacokinetic Analyses Non‐compartmental pharmacokinetic analyses were performed on individual concentration–time profiles using the PKNCA package, v0.12.1 [16] in R version 4.2.2 [17]. Baseline concentrations below the lower limit of quantification (LLOQ: 300 pg·mL−1) were treated as zero and were excluded from the analysis. Samples not obtained or not analyzable were treated as missing. The following pharmacokinetic parameters were derived for each participant: The maximum plasma concentration, C max, was obtained directly from the observed concentration–time profiles. The maximum plasma concentration, C max, was obtained directly from the observed concentration–time profiles. The area under the concentration–time curve from time zero to the last measurable concentration, AUC0–90, was estimated using the linear trapezoidal rule. The area under the concentration–time curve from time zero to the last measurable concentration, AUC0–90, was estimated using the linear trapezoidal rule. The terminal elimination rate constant (λ z ) was determined by log‐linear regression of concentrations in the terminal phase (at least three points) of the concentration‐time curve. The terminal elimination rate constant (λ z ) was determined by log‐linear regression of concentrations in the terminal phase (at least three points) of the concentration‐time curve. The terminal elimination half‐life (t 1/2) was calculated as ln (2)/λ z . The terminal elimination half‐life (t 1/2) was calculated as ln (2)/λ z . The area under the concentration‐time curve from time zero to infinity AUC0–∞ was calculated as AUC90 + (C90/λ z ). The area under the concentration‐time curve from time zero to infinity AUC0–∞ was calculated as AUC90 + (C90/λ z ). Systemic clearance (CL) was obtained as Dose/AUC0–∞ and expressed per kilogram of body weight. Systemic clearance (CL) was obtained as Dose/AUC0–∞ and expressed per kilogram of body weight. Apparent (terminal) volume of distribution (V d ) was calculated as CL/λ z . Apparent (terminal) volume of distribution (V d ) was calculated as CL/λ z . All pharmacokinetic parameters were reported using the original concentration scale (pg·mL−1). Time was analyzed in minutes. Doses were normalized to body weight. Clinical Outcomes Emergence behavior (Watcha score, PAED), postoperative pain, time to awakening, and time to discharge readiness were analyzed descriptively. Adverse events are presented as counts. The sample size did not allow formal PK/PD modeling. Statistical Considerations Data were assessed for normality via visual inspection. Data are presented as mean (SD) or median [IQR] according to their distribution. No statistical tests were performed on the clinical outcomes due to the nature and size of the data. All data were managed and analyzed in RStudio. Results Twenty children aged 2–6 years were enrolled. Demographic characteristics are reported in Table 1. Participants were treated for cryptorchidism, hypospadias, phimosis, hernia, or other minor procedures. Eleven participants received sevoflurane, four of whom had sevoflurane during maintenance of anesthesia. The remaining participants received total intravenous anesthesia. All enrolled participants completed the study. TABLE 1Demographic characteristics. N = 20Age (years)5.02 (1.20)Male sex18 (90.0%)Weight (kg)18.1 [17.25, 20.23]Height (cm)110 (7.65)BMI (kg·m−2)15.8 (1.62)ProcedureHypospadias repair6 (30%)Cryptorchidism repair5 (25%)Phimosis repair3 (15%)Umbilical/inguinal hernia repair3 (15%)Coloscopy/cystoscopy/other minor procedure3 (15%)Premedication with oral midazolam (0.5 mg·kg−1)4 (20%)Anxiety score before induction (mYPAS‐SF)39.6 [33.33, 54.17] Note: N (%), mean (SD), or median [IQR] according to variable and distribution. There were no missing data in baseline variables.Abbreviations: BMI, body mass index; IQR, interquartile range; SD, standard deviation. Demographic characteristics. Note: N (%), mean (SD), or median [IQR] according to variable and distribution. There were no missing data in baseline variables. Abbreviations: BMI, body mass index; IQR, interquartile range; SD, standard deviation. Pharmacokinetic Analyses One hundred nineteen plasma concentration samples were analyzed. One blood sample was missed due to a malfunctioning intravenous cannula. Twenty baseline samples under the LLOQ were excluded. In addition to those, an outlier with a value 25 times the mean concentration of first samples was excluded. The excluded outlier (also a first sample) was attributed to contamination. In total, 98 plasma samples were included in the pharmacokinetic analysis. Individual plasma concentrations over time are illustrated in Figure 1, and log‐transformed time–concentration profiles are illustrated in Figure S1. Individual melatonin time–concentration profiles. Pharmacokinetic parameters are summarized in Table 2. Peak plasma concentration (C max) was 416 298 [322 230–508 006] pg·mL−1 an elimination half‐life (t 1/2) was 35.20 (8.41) minutes. Total exposure (AUC0–∞) was 8 352 522 [7 287 183–9 181 133] pg·min·mL−1. The terminal phase was well characterized, with mean (SD) adjusted r 2 values of 0.986 (0.029) and a low proportion of extrapolated AUC0–∞ of 14.5% (6.46). Clearance (CL) was 0.0183 (0.0039) L·min−1·kg−1, and volume of distribution (V d ) was 0.92 (0.27) L·kg−1. TABLE 2Pharmacokinetic parameters of intravenous melatonin.VariableUnitMeanSDCV (%)MedianIQRMinimumMaximum C max pg·mL−1 416 719.80170 557.5140.9416 297.50322 229.75–508 005.75128 404.00809 767.00 t 1/2 min35.208.4123.933.4229.23–40.7124.3050.16AUC0–∞ pg·min·mL−1 8 568 258.311 925 910.7922.58 352 522.127 287 182.82–9 181 132.875 533 148.3213 012 953.96CLL·min−1·kg−1 0.01830.003921.30.01810.0164–0.02080.01150.0267 V d L·kg−1 0.920.2729.10.830.72–1.140.581.49Abbreviations: AUC0–∞, area under the concentration–time curve extrapolated to infinity; CL, apparent total clearance; C max, maximum observed plasma concentration; CV (%), coefficient of variation; IQR, interquartile range; SD, standard deviation; t 1/2, terminal elimination half‐life; V d , apparent volume of distribution. Pharmacokinetic parameters of intravenous melatonin. Abbreviations: AUC0–∞, area under the concentration–time curve extrapolated to infinity; CL, apparent total clearance; C max, maximum observed plasma concentration; CV (%), coefficient of variation; IQR, interquartile range; SD, standard deviation; t 1/2, terminal elimination half‐life; V d , apparent volume of distribution. Clinical Parameters Clinical outcomes are presented in Table 3. No participant fulfilled the criteria for the definition of emergence agitation or delirium (Watcha > 2 and PAED ≥ 10, respectively). Maximal pain scores during PACU stay had a mean (SD) of 1.30 (1.95) with a maximum of 5. Time to awakening and discharge averaged 63 and 119 min, respectively. PHBQ‐AS scores from the day after surgery yielded a median [IQR] of 3.18 [3.09, 3.32]. TABLE 3Clinical outcomes. N = 20Emergence agitation a 0Maximum Watcha score b 1.15 (0.37)PAED score c 4.37 (2.43)Missing d 1 (5.0%)Maximum FLACC score b 1.30 (1.95)Time to awakening (min) e 63.0 [50.50, 76.25]Time to discharge readiness (min) e 118.5 [86.75, 149.75]PHBQ‐AS score f 3.18 [3.09, 3.32]Missing d 1 (5.0%) Note: N, mean (SD), and median [IQR] according to variable and distribution.Abbreviations: IQR, interquartile range; SD, standard deviation. a Emergence agitation was defined as Watcha > 2 or PAED ≥ 10. b Watcha (1–4) and FLACC (0–10) were measured every 15 min in PACU. c PAED (0–20) was measured at 10 min after awakening. d Missingness is only described for variables with missing values. e Time to awakening and time to discharge are calculated from end of anesthesia. f PHBQ‐AS score is from 24‐hour follow‐up phone interview. Clinical outcomes. Note: N, mean (SD), and median [IQR] according to variable and distribution. Abbreviations: IQR, interquartile range; SD, standard deviation. Emergence agitation was defined as Watcha > 2 or PAED ≥ 10. Watcha (1–4) and FLACC (0–10) were measured every 15 min in PACU. PAED (0–20) was measured at 10 min after awakening. Missingness is only described for variables with missing values. Time to awakening and time to discharge are calculated from end of anesthesia. PHBQ‐AS score is from 24‐hour follow‐up phone interview. Adverse Events A total of 10 adverse events and two serious adverse events were recorded (Table 4). Most adverse events were complaints of postoperative pain. The SAEs referred to one ambulatory surgical case that required rehospitalization for postoperative pain due to complications related to the placement of a urinary catheter and one ambulatory surgical case that required rehospitalization due to postoperative urinary retention the day after surgery. Both SAEs were resolved, and participants recovered without sequelae. TABLE 4Adverse events, n (%). N = 20EventsIndividualsNumber of adverse events107 (35)Number of serious adverse events22 (10)Participants with zero adverse events13 (65)Participants with one adverse event4 (20)Participants with more than one adverse event3 (15)Type of adverse eventsIn the PACUPostoperative pain6 (30)Nausea1 (5)Follow‐up interviewPostoperative pain2 (10)Headache1 (5) Adverse events, n (%). Discussion To our knowledge, this is the first study to investigate intravenous melatonin in preschool‐aged pediatric surgical patients. We investigated a cohort of pediatric patients aged 2–6 years undergoing general anesthesia and surgery receiving a single bolus of melatonin 0.15 mg·kg−1 30 min before end of surgery. We found pharmacokinetic parameters largely consistent with those previously reported in adult populations. Notably, we found a half‐life of 35 min, comparable to adult studies reporting half‐lives of 28–60 min for intravenous doses of melatonin ranging from 0.005 to 100 mg [8, 18]. In line with our r 2‐values (mean 0.986), t 1/2 and AUC0–∞ estimates yielded low variability of 24% and 23%, respectively. Weight‐normalized clearance (0.0183 L·min−1·kg−1) and distribution volume (0.9 L·kg−1) were also comparable to data on intravenous administration of 10 mg in adults, demonstrating clearances of 0.0218–0.253 L·min−1·kg−1 and mean volumes of 1.2–1.6 L·kg−1 [18, 19]. Clearance exhibited low inter‐individual variability (21%). In contrast, the modestly higher variability in volume of distribution (29%) may be attributable to age‐related differences in body composition across the cohort. Only a few studies have investigated the pharmacokinetics of an intravenous melatonin bolus in pediatric populations. Cavallo and Ritschel [11] studied prepubertal children over 6 years of age who received 0.5 μg·kg−1 and found a similar half‐life of approximately 40 min but somewhat higher clearance of 0.044 L·min−1·kg−1. Authors argued that there might be a window of faster melatonin metabolism in prepubertal children that correlates with sexual maturation [11]. Studies in neonates mainly include melatonin infusions or oral administration but appear to show prolonged elimination half‐lives as well as reduced clearance [10, 12, 20]. An important finding is the mean C max of 416 719 pg·mL−1 in our cohort with an inter‐individual variability of 41%. While the variability is higher than for other pharmacokinetic parameters, it is lower than for oral studies and thus invariably also reflects the benefits of intravenous administration over oral administration. This is especially relevant when predictable dosing and timing are preferred, such as in perioperative pediatric settings. Our study is not powered nor designed for formal analyses on clinical outcomes. However, we note that none of the participants experienced emergence delirium, and overall maximum pain scores were acceptable. Times to awakening and discharge were comparable to usual values in our institution [21, 22]. These findings are purely descriptive and do not imply a melatonin effect on clinical outcomes. Importantly, adverse events and serious adverse events reported in this cohort were linked to postoperative complications such as postoperative pain and postoperative urinary retention and were thus unrelated to the administration of melatonin. In addition to those, one participant experienced nausea in PACU, and one reported a headache the day after surgery—both common postoperative side effects. Although these findings cannot be interpreted in isolation, they align with a growing body of evidence supporting the safety of short‐term melatonin treatment, particularly in the perioperative setting and extending to the pediatric population [1, 2, 4, 5]. This study is the first to employ a novel intravenous melatonin formulation specifically developed for pediatric use. Samples were analyzed with a validated HPLC‐FLD method, and our non‐compartmental pharmacokinetic analyses yielded good terminal‐phase fits. The enrolled participants had routine pediatric surgery, which increases external validity. We acknowledge some limitations related to our study design. First, the use of an intravenous formulation restricts the use to patients with an intravenous cannula. As such, this formulation was not primarily intended to serve as a premedicant, although melatonin has most often been investigated for its beneficial effects on preoperative anxiety [4]. Second, as in most pharmacokinetic studies, especially in the pediatric population [8], our study included a limited study population, with a majority of male participants, and a limited number of samples, which may affect generalizability. Although the proportion of extrapolated AUC was small (~14%), an extended sampling window may have further refined our terminal‐phase estimates. However, this short intensive sampling schedule was chosen for feasibility purposes in this pediatric surgical population, where a maximum of samples was taken during anesthesia or sleep, and where sampling was done under consideration for minimal interference in the important recovery phase after anesthesia. We used non‐compartmental analysis for these data to provide an initial descriptive characterization of intravenous melatonin pharmacokinetics in children. Population pharmacokinetic modeling could allow exploration of covariate effects and potential anesthetic state‐dependent changes in clearance during anesthesia and recovery in future studies. Perioperative physiological changes and anesthetic management may also influence melatonin pharmacokinetics. General anesthesia may alter hemodynamics and hepatic blood flow [23], and propofol anesthesia, including its lipid formulation [24], might have influenced melatonin distribution. The surgical procedures carried out in this study were short, and perioperative fluid administration was minimal and hence, unlikely to affect distribution volumes meaningfully. The present study was not designed to evaluate these potential effects separately; they should, however, be considered when interpreting perioperative melatonin pharmacokinetics. Finally, the LLOQ of the HPLC method developed did not allow for a quantification of our baseline samples. Commercially available immunoassays might have been able to provide values for those, but there were several reasons to prefer an in‐house HPLC method over commercially available assays. Firstly, our samples would have required extensive dilution to reach the analytical range of commercial immunoassays. This could introduce variability from the dilution itself, and such dilute samples would no longer match the sample matrix of the assay. Furthermore, immunoassays are known to be prone to erroneous measurements [25], which also holds true for melatonin immunoassays [26]. Even relatively small errors in measurement would cause a significant difference once the dilution factor is considered. The HPLC‐FLD method was developed specifically to measure the high values expected in a pharmacokinetic study. The main drawback of this method, however, is that fluorescence detection struggles to detect endogenous levels of melatonin, which, during daytime, are expected to be ≥ 5 pg·mL−1 and ≥ 100 pg·mL−1 at night [27]. Given this very low expected endogenous level of melatonin, there would be no appreciable effect on pharmacokinetic parameters such as C max, AUC, CL, or V d . All baseline samples, collected between 8 a.m. and 2 p.m., were confirmed to be below the LLOQ and were therefore not included in the analyses. Newer liquid chromatography–tandem mass spectrometry (LC–MS/MS) methods may effectively mitigate these issues in future studies [28]. In conclusion, an intravenous melatonin dose of 0.15 mg·kg−1 administered 30 min before the end of surgery in preschool children yielded pharmacokinetic parameters comparable to adults. Adverse events could be attributed to known postoperative symptoms. Our findings can inform dose selection for perioperative trials in children. Future research should explore the effect of intravenous melatonin on the recovery profile in children undergoing anesthesia and surgery, preferably in randomized controlled settings such as the ongoing MELA‐PAED trial [9]. Funding The study has received funding from Oberstinde Kirsten Jensa La Cours Legat, Lægeforeningens Forskningsfond, The Danish Society of Anesthesiology and Intensive Care (DASAIM), Dagmar Marshalls Fond, Kong Christian den Tiendes Fond, and Lippmann Fonden. The MELA‐PAED trial is funded by a grant from Sundhedsdonationer (2024‐0383). A.L.B.G. is funded by a Ph.D. stipend from Rigshospitalet Research Grants. Ethics Statement This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Danish National Committee in Health Research Ethics (EU CT 2024‐517592‐20). Consent Written informed consent was obtained from both parents of each participant in the study. Conflicts of Interest The research group (A.L.B.G., A.A., L.P.K.A.) is currently carrying out the randomized MELA‐PAED trial, investigating the effect of intravenous melatonin on the prevention of emergence delirium. A patent application has been filed concerning the melatonin formulation used in this study (Application No. 25203641.3) by Rigshospitalet. A.L.B.G., A.A., K.Ø.N., and L.P.K.A. are named as inventors. Supporting information Figure S1: Individual plasma concentration profiles (log‐transformed data). Acknowledgments We thank the participants and their families for their participation in the study. We thank the staff of the Department of Anesthesiology, Juliane Marie Center, Rigshospitalet, for their assistance with the study. We thank the staff at Glostrup Pharmacy, Glostrup, Denmark, for assistance in the development of the intravenous formulation of melatonin used in this study. Data Availability Statement The data that support the findings of this study are available upon reasonable request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions. References Associated Data Supplementary Materials Figure S1: Individual plasma concentration profiles (log‐transformed data). Data Availability Statement The data that support the findings of this study are available upon reasonable request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.